Xeris Biopharma (NASDAQ:XERS) Insider Sells 16,666 Shares

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Beth Hecht sold 16,666 shares of the stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $8.49, for a total transaction of $141,494.34. Following the sale, the insider directly owned 1,127,796 shares in the company, valued at $9,574,988.04. This trade represents a 1.46% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Beth Hecht also recently made the following trade(s):

• On Monday, August 3rd, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The stock was sold at an average price of $8.01, for a total transaction of $133,494.66.
• On Wednesday, July 1st, Beth Hecht sold 16,666 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.03, for a total transaction of $133,827.98.

Xeris Biopharma Stock Down 0.1%

NASDAQ XERS traded down $0.01 during mid-day trading on Tuesday, reaching $8.43. The stock had a trading volume of 1,144,088 shares, compared to its average volume of 1,849,041. The stock has a market cap of $1.54 billion, a PE ratio of -76.64 and a beta of 0.66. Xeris Biopharma Holdings, Inc. has a 1 year low of $5.25 and a 1 year high of $10.08. The company has a debt-to-equity ratio of 17.00, a current ratio of 1.45 and a quick ratio of 1.02. The company has a fifty day moving average price of $8.32 and a 200 day moving average price of $6.93.

Xeris Biopharma (NASDAQ:XERS) last posted its earnings results on Thursday, August 6th. The company reported ($0.18) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.19). Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%.The business had revenue of $92.10 million during the quarter, compared to the consensus estimate of $90.12 million. On average, research analysts expect that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current year.

Hedge Funds Weigh In On Xeris Biopharma

Hedge funds have recently modified their holdings of the company. Kestra Advisory Services LLC bought a new stake in shares of Xeris Biopharma during the 4th quarter valued at $25,000. Allworth Financial LP bought a new position in Xeris Biopharma in the 2nd quarter worth $34,000. KBC Group NV purchased a new stake in Xeris Biopharma in the 1st quarter worth $27,000. State of Wyoming bought a new stake in Xeris Biopharma during the second quarter valued at about $52,000. Finally, Caitong International Asset Management Co. Ltd raised its holdings in Xeris Biopharma by 9,276.3% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 7,501 shares of the company’s stock valued at $59,000 after acquiring an additional 7,421 shares during the period. 42.75% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

XERS has been the subject of a number of recent research reports. Weiss Ratings downgraded Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Wall Street Zen cut Xeris Biopharma from a “strong-buy” rating to a “buy” rating in a report on Saturday, August 8th. Finally, Barclays lifted their target price on Xeris Biopharma from $9.00 to $12.00 and gave the company an “overweight” rating in a research report on Thursday, August 20th. Three research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $12.00.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.